NCT02500225

Comparison the Effects of Etomidate and Sevoflurane During Electroconvulsive Therapy

Ulku Ozgul, Associate Professor, Inonu University, Department of Anesthesiology and Reanimation

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Inonu University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study was to investigate the effects of etomidate or sevoflurane used in electroconvulsive therapy (ECT) on duration of seizure, hemodynamic response and recovery profiles.

Detailed description

Twenty-five patients will be a total of 150 ECT treatments in this prospective, double-blinded, crossover study. Each patient will receive either 0.2 mg/kg etomidate (Group 1) or 8% sevoflurane (Group 2) in 100% oxygen at 6 L/min fresh gas flow until loss of consciousness for their initial electroconvulsive therapy session. In subsequent sessions, patients will receive the alternative sevoflurane concentration and then alternated between doses until the sixth session. Muscle paralysis will achieve with 1 mg/kg succinylcholine. Motor (EMG) and electroencephalography seizure duration (EEG), heart rate (HR) and mean arterial pressure (MAP) values, and recovery times will recorde.

Conditions

• Anesthesia
• ECT

Interventions

Type	Name	Description
DRUG	Etomidate	0.2 mg/kg etomidate
DRUG	Sevoflurane	8% Sevoflurane

Timeline

• Start date: 2017-01-01
• Primary completion: 2017-02-01
• Completion: 2017-02-01
• First posted: 2015-07-16
• Last updated: 2019-01-23